Stent directo vs angioplastia convencional y sus interacciones con la trombo-aspiración

Bioresorbable scaffolds with drug-eluting stents: do they entail a higher thrombosis risk?

Courtesy of Dr. Leiva. Bioresorbable scaffolds with drug-eluting stents (bioresorbable vascular scaffolds, BVS) have been added to the list of endovascular treatment options for coronary disease. The ABSORB III trial showed the non-inferiority of this stent type to everolimus-eluting metallic stents as regards target-lesion revascularization (TLR) at one year. However, reports have suggested a higher<a href="https://solaci.org/en/2017/04/21/bioresorbable-scaffolds-with-drug-eluting-stents-do-they-entail-a-higher-thrombosis-risk/" title="Read more" >...</a>

Very Late Thrombosis: Bioresorbable Scaffolds vs. Everolimus-Eluting Metallic Drug-Eluting Stents

This study sought to compare the 2-year outcomes between bioresorbable vascular scaffolds (BVS) and everolimus-eluting metallic drug-eluting stents (EES), since the occurrence of very late thrombosis (thrombosis beyond 1 year after implantation) is an increasing concern in relation to new devices.   This meta-analysis was conducted based on 24 studies (BVS: n = 2567 and EES: n = 19,806) reporting the<a href="https://solaci.org/en/2017/01/24/very-late-thrombosis-bioresorbable-scaffolds-vs-everolimus-eluting-metallic-drug-eluting-stents/" title="Read more" >...</a>

Transcatheter Valve Thrombosis: Predictors, Incidence, and Events

This study sought to clarify the incidence and predictors of hypoattenuated leaflet thickening (assumed as leaflet thrombosis) imaging in transcatheter bioprosthesis.   This study involved 70 consecutive patients who underwent transcatheter aortic valve replacement with the Edwards SAPIEN-XT device and were subjected to follow-up at 6 months and 1 year through multislice computed tomography (CT), echocardiographic data, and<a href="https://solaci.org/en/2017/01/21/transcatheter-valve-thrombosis-predictors-incidence-and-events/" title="Read more" >...</a>

Valve Thrombosis After TAVR: Larger-Diameter Valves and No Warfarin as Predictors

There are limited data on the incidence, clinical implications, and predisposing factors of valve thrombosis in patients who underwent transcatheter aortic valve replacement (TAVR). This study aimed at determining such information through multislice computed tomography (CT).   This trial included 460 consecutive patients who underwent TAVR with a balloon-expandable Edwards Sapien XT or Sapien 3 (Edwards Lifesciences,<a href="https://solaci.org/en/2016/11/13/valve-thrombosis-after-tavr-larger-diameter-valves-and-no-warfarin-as-predictors/" title="Read more" >...</a>

A Study on Valve Thrombosis After TAVI

This study, presented in Rome at the European Society of Cardiology Congress 2016 and published simultaneously online in the Journal of the American College of Cardiology (JACC), has identified a post-TAVI valve thrombosis rate of 7% using multidetector computerized tomography (CT). However, the vast majority of cases were completely asymptomatic.   Previous studies had shown<a href="https://solaci.org/en/2016/09/07/a-study-on-valve-thrombosis-after-tavi/" title="Read more" >...</a>

Stent thrombosis: Comparative analysis between BMS, DES and BRS

Original Title: Stent Thrombosis with Drug Eluting Stents and Bioresorbable Scaffolds. Evidence from a Network Meta-Analysis of 147 trials. Reference: Kang S et al. J Am Coll Cardiol Intv 2016 doi 10.1016. Courtesy of Dr. Guillermo Migliaro.   When treating heart disease, drug eluting stents (DES) have become essential for PCI. Its main advantage lies on<a href="https://solaci.org/en/2016/06/13/stent-thrombosis-comparative-analysis-between-bms-des-and-brs/" title="Read more" >...</a>

Bioresorbable Scaffold Thrombosis: incidence, risk factors and possible mechanism

Original Title: Bioresorbable Vascular Scaffold Thrombosis. Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors. Reference: Puricel S et al. J Am Coll Cardiol 2016;67:921-31. Courtesy of Dr. Guillermo Migliaro. Bioresorbable scaffolds (BVS) were introduced in interventional cardiology to avoid late DES complications. However, recent reports suggest an elevated incidence of thrombosis with these new devices.<a href="https://solaci.org/en/2016/03/29/bioresorbable-scaffold-thrombosis-incidence-risk-factors-and-possible-mechanism/" title="Read more" >...</a>

Mechanisms of Very Late DES Thrombosis by OCT

Original Title: Mechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography. Reference: Masanori Taniwaki et al. Circulation. 2016 Feb 16;133(7):650-60.   The physiopathological mechanisms behind DES thrombosis have not been fully described yet. The potential causes behind this adverse event were assessed using optical computed tomography (OCT). Between August 2010 and December 2014,<a href="https://solaci.org/en/2016/03/29/mechanisms-of-very-late-des-thrombosis-by-oct/" title="Read more" >...</a>

Femoropopliteal Artery Stent Thrombosis

Original Title: Femoropopliteal Artery Stent Thrombosis. Report from the Excellence in Peripheral Artery Disease Registry. Reference: Subhash Banerjee et al. Circ Cardiovasc Interv. 2016 Feb;9(2):e002730.   There is limited information on peripheral stent thrombosis and involved factors. This study analyzed 604 stent procedures in femoropopliteal territory form the multicenter registry “Excellence in Peripheral Artery Disease”. Stent<a href="https://solaci.org/en/2016/03/10/femoropopliteal-artery-stent-thrombosis/" title="Read more" >...</a>

Definite/Probable Thrombosis with Bioresorbable Scaffolds

Original Title: Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold. A Systematic Review and Meta-Analysis. Reference: Michael J. Lipinski et al. J Am Coll Cardiol Intv. 2016;9(1):12-24. The authors of this study carried out a systematic review and a meta-analysis to determine the thrombosis risk of the bioresorbable everolimus eluting scaffold ABSORB (Abbott<a href="https://solaci.org/en/2016/01/27/definite-probable-thrombosis-with-bioresorbable-scaffolds/" title="Read more" >...</a>